CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Fesoterodinedrug
Likely dose
Fesoterodine 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00857896
NCT00857896Phase 2Completed
CompareCT.gov

An Open-Label, Dose-Escalating Study Of The Pharmacokinetics, Safety And Tolerability Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years.

Pfizer·interventional·Posted Mar 9, 2009·Updated Nov 24, 2011

In Brief

A Phase 2 clinical trial evaluating Fesoterodine for Overactive Bladder and Neurogenic Detrusor Overactivity. Completed, enrolled 21 participants across 9 sites.

Detailed Summary

The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder, Neurogenic Detrusor Overactivity
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 9, 2009
Enrollment StartMar 1, 2009
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.3 years ago

Interventions

Fesoterodinedrug

4 mg once daily for Weeks 1-4 and 8 mg once daily for Weeks 5-8